These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

649 related items for PubMed ID: 25468432

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL, Liu YH, Zhang F, Xu FP, Yan LX, Chen J, Xu J, Luo XL, Zhuang HG.
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, Nielsen O, Gadeberg OV, Mourits-Andersen T, Frederiksen M, Pedersen LM, Møller MB.
    J Clin Oncol; 2012 Oct 01; 30(28):3460-7. PubMed ID: 22665537
    [Abstract] [Full Text] [Related]

  • 4. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR.
    Am J Surg Pathol; 2010 Mar 01; 34(3):327-40. PubMed ID: 20118770
    [Abstract] [Full Text] [Related]

  • 5. New insights into the biology of molecular subtypes of diffuse large B-cell lymphoma and Burkitt lymphoma.
    Frick M, Dörken B, Lenz G.
    Best Pract Res Clin Haematol; 2012 Mar 01; 25(1):3-12. PubMed ID: 22409819
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, Scott DW, Tan KL, Steidl C, Sehn LH, Chan WC, Iqbal J, Meyer PN, Lenz G, Wright G, Rimsza LM, Valentino C, Brunhoeber P, Grogan TM, Braziel RM, Cook JR, Tubbs RR, Weisenburger DD, Campo E, Rosenwald A, Ott G, Delabie J, Holcroft C, Jaffe ES, Staudt LM, Gascoyne RD.
    J Clin Oncol; 2012 Oct 01; 30(28):3452-9. PubMed ID: 22851565
    [Abstract] [Full Text] [Related]

  • 13. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K, Dimitrova L, Oker E, Tomaszewski N, Berg E, Taruttis F, Engelmann JC, Schwarzfischer P, Reinders J, Spang R, Gronwald W, Oefner PJ, Hummel M.
    BMC Cancer; 2019 Apr 05; 19(1):322. PubMed ID: 30953469
    [Abstract] [Full Text] [Related]

  • 14. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia.
    Slack GW, Steidl C, Sehn LH, Gascoyne RD.
    Br J Haematol; 2014 Dec 05; 167(5):608-17. PubMed ID: 25135752
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.
    Dunleavy K.
    Curr Treat Options Oncol; 2015 Dec 05; 16(12):58. PubMed ID: 26634708
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Burkitt lymphoma versus diffuse large B-cell lymphoma: a practical approach.
    Bellan C, Stefano L, Giulia de F, Rogena EA, Lorenzo L.
    Hematol Oncol; 2010 Jun 05; 28(2):53-6. PubMed ID: 19844983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.